Equities analysts expect that Cellectis S.A. (NASDAQ:CLLS) will post $11.50 million in sales for the current quarter, Zacks reports. Two analysts have made estimates for Cellectis’ earnings. The highest sales estimate is $12.00 million and the lowest is $11.00 million. Cellectis reported sales of $9.24 million during the same quarter last year, which indicates a positive year-over-year growth rate of 24.5%. The firm is expected to issue its next earnings report on Thursday, November 4th.
According to Zacks, analysts expect that Cellectis will report full year sales of $65.73 million for the current year, with estimates ranging from $63.00 million to $67.60 million. For the next fiscal year, analysts expect that the company will post sales of $87.90 million, with estimates ranging from $36.80 million to $168.90 million. Zacks’ sales calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Cellectis.
Cellectis (NASDAQ:CLLS) last announced its quarterly earnings results on Thursday, August 5th. The biotechnology company reported ($0.88) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.75) by ($0.13). Cellectis had a negative net margin of 181.89% and a negative return on equity of 39.99%. The business had revenue of $14.62 million during the quarter, compared to analysts’ expectations of $12.43 million.
CLLS stock traded up $0.06 during trading on Friday, hitting $13.92. The stock had a trading volume of 5,848 shares, compared to its average volume of 294,393. The company has a debt-to-equity ratio of 0.08, a current ratio of 5.45 and a quick ratio of 5.40. Cellectis has a twelve month low of $11.88 and a twelve month high of $34.71. The stock has a market capitalization of $632.82 million, a P/E ratio of -4.94 and a beta of 2.37. The company’s 50-day moving average price is $13.88 and its two-hundred day moving average price is $16.32.
Large investors have recently added to or reduced their stakes in the stock. Royal Bank of Canada raised its stake in shares of Cellectis by 36.8% in the 1st quarter. Royal Bank of Canada now owns 7,166 shares of the biotechnology company’s stock valued at $146,000 after buying an additional 1,926 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in shares of Cellectis in the 1st quarter valued at $39,000. Envestnet Asset Management Inc. raised its stake in shares of Cellectis by 3.2% in the 1st quarter. Envestnet Asset Management Inc. now owns 75,596 shares of the biotechnology company’s stock valued at $1,528,000 after buying an additional 2,373 shares in the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. raised its stake in shares of Cellectis by 14.5% in the 2nd quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 19,211 shares of the biotechnology company’s stock valued at $297,000 after buying an additional 2,433 shares in the last quarter. Finally, Blair William & Co. IL raised its stake in shares of Cellectis by 21.0% in the 1st quarter. Blair William & Co. IL now owns 14,400 shares of the biotechnology company’s stock valued at $291,000 after buying an additional 2,500 shares in the last quarter. Hedge funds and other institutional investors own 35.71% of the company’s stock.
Cellectis Company Profile
Cellectis SA engages as a biopharmaceutical company that harnesses the immune system to target and eradicate cancer cells. It offers Gene editing and Immuno-oncology. The company was founded by David J. Sourdive and André Choulika on February 20, 1999 and is headquartered in Paris, France.
Further Reading: How to read a candlestick chart
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.